Drug limits kidney rejection
The anti-leukemia drug alemtuzumab (Campath) can lessen the risk of immune rejection in some people receiving a kidney transplant, a new study finds. But the results, published in the May 19 New England Journal of Medicine, suggest that the drug doesn’t improve prospects for the patients most prone to rejecting a transplant.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.